Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genakumab for prevention of gout flares during ULT initiation
NCT05936281Phase 2Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of genakumab in gout, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Jul 2023; status: completed.
02
Drugs
genakumab
03
Conditions
gout
Beyond the preview
Go deeper on NCT05936281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05936281.